Dr. Mohamed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 W Thomas Rd
Ste 300A
Phoenix, AZ 85013Phone+1 602-406-4000Fax+1 602-406-6498
Education & Training
Yale-New Haven Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2013- Yale-New Haven Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2011
Norwalk Hospital/Yale UniversityFellowship, Pulmonary Disease, 2011 - 2013
University of Nevada Reno School of MedicineResidency, Internal Medicine, 2006 - 2009
University of Tripoli School of MedicineClass of 1995
Certifications & Licensure
AZ State Medical License 2019 - 2026
NV State Medical License 2009 - 2021
WV State Medical License 2015 - 2021
VA State Medical License 2014 - 2020
NM State Medical License 2007 - 2008- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
Publications & Presentations
PubMed
- 3 citationsHot Tub Lung: A Diagnostic Challenge.Hassaan Yasin, William E Mangano, Paras Malhotra, Ali Farooq, Hesham Mohamed
Cureus. 2017-08-27 - 11 citationsBronchopleural Fistula as a Complication in a COVID-19 Patient Managed With Endobronchial ValvesAndrew Talon, Muhammad Arif, Hesham Mohamed, Abid Khokar, Ali Saeed
Journal of Investigative Medicine High Impact Case Reports. 2021-04-30 - 2 citationsPulmonary Langerhans Cell Histiocytosis Associated with Bronchogenic Carcinoma.Muhammad Farhan Khaliq, Muhammad Muslim Noorani, Syed Maaz Tariq, Ashish Koirala, Hesham Mohamed
Cureus. 2020-01-12
Abstracts/Posters
- Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...Hesham Mohamed, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Hesham Mohamed, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
